...
首页> 外文期刊>JACC. Cardiovascular interventions >Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions
【24h】

Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions

机译:杂交经皮冠状动脉介入与生物吸收的血管支架,与药物洗脱支架或药物涂层气球组合,用于复杂冠状病变

获取原文
获取原文并翻译 | 示例
           

摘要

Bioresorbable vascular scaffolds (BVS) have become an attractive option in the percutaneous coronary intervention field due to the potential advantages associated with the complete resorption process that occurs within a few years. However, current-generation BVS have several limitations including thicker struts, reduced radial strength, and limited expansion capability when compared with drug-eluting stents (DES). As a result, complex coronary disease often contains BVS-inappropriate/unfavorable segments. This does not necessarily mean that BVS use must be completely avoided, and minimizing the length of permanent metallic caging may still be advantageous. Operators should fully understand the limitations of current BVS, and when to consider a hybrid strategy of BVS in combination with DES or drug-coated balloons. (C) 2017 by the American College of Cardiology Foundation.
机译:由于与在几年内发生的完整吸收过程相关的潜在优势,生物吸收血管支架(BVS)已成为经皮冠状动脉干预领域的有吸引力的选择。 然而,与药物洗脱支架(DES)相比,电流发电BVS具有几个限制,包括较厚的支柱,降低径向强度和有限的膨胀能力。 结果,复杂的冠状动脉疾病通常含有BVS - 不适当/不利的段。 这并不一定意味着必须完全避免使用BVS使用,并且最小化永久金属笼的长度可能仍然是有利的。 运营商应充分了解当前BV的局限性,以及何时考虑BVS的混合策略与DES或药物涂层的气球结合。 (c)2017年由美国心脏病学基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号